FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014019655007/17/14Systems and devices for sample handling
22014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
32014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
42014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
52014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
62014017887906/26/14Compositions and methods for modifying cells
72014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
82014015470106/05/14Humanized fc gamma r mice
92014015568906/05/14Methods of modifying genes in eukaryotic cells
102014015744506/05/14Low affinity fcgr deficient mice
112014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
122014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
132014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
142014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
152014013471905/15/14Recombinant cell surface capture proteins
162014013727505/15/14Hybrid light chain mice
172014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
182014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
192014013471905/15/14Recombinant cell surface capture proteins
202014013727505/15/14Hybrid light chain mice
212014013019305/08/14Mice that make vl binding proteins
222014013019405/08/14Mice that make vl binding proteins
232014013019305/08/14Mice that make vl binding proteins
242014013019405/08/14Mice that make vl binding proteins
252014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
262014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
272014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
282014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
292014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
302014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
312014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
322014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
332014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
342014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
352014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
362014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
372014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
382014007297903/13/14Isolating cells expressing secreted proteins
392014007298003/13/14Isolating cells expressing secreted proteins
402014007301003/13/14Methods of modifying eukaryotic cells
412014007558603/13/14Parental cell lines for making cassette-free f1 progeny
422014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
432014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
442014007297903/13/14Isolating cells expressing secreted proteins
452014007298003/13/14Isolating cells expressing secreted proteins
462014007301003/13/14Methods of modifying eukaryotic cells
472014007558603/13/14Parental cell lines for making cassette-free f1 progeny
482014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
492014005690702/27/14Anti-asic1 antibodies and uses thereof
502014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
512014004106802/06/14Methods of modifying eukaryotic cells
522014003333601/30/14Methods of modifying eukaryotic cells
532014003333701/30/14Methods of modifying eukaryotic cells
542014002363701/23/14Methods of modifying eukaryotic cells
552014001722801/16/14Humanized light chain mice
562014001722901/16/14Methods of modifying eukaryotic cells
572014001723801/16/14Methods of modifying eukaryotic cells
582014001769501/16/14Isolating cells expressing secreted proteins
592014001778101/16/14Methods of modifying eukaryotic cells
602014001778201/16/14Methods for modifying eukaryotic cells
612014001852201/16/14Methods of modifying eukaryotic cells
622014002012401/16/14Methods of modifying eukaryotic cells
632014002012501/16/14Methods of modifying eukaryotic cells
642014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
652014001345701/09/14Methods of modifying eukaryotic cells
662013034453812/26/13Human antibodies to the glucagon receptor
672013034010412/19/13Humanized il-7 rodents
682013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
692013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
702013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
712013032326112/05/13Purified antibody composition
722013032378812/05/13Production cell line enhancers
732013032379012/05/13Human lambda light chain mice
742013032379112/05/13Restricted immunoglobulin heavy chain mice
752013032664712/05/13Human lambda light chain mice
762013030967011/21/13Nuclease-mediated targeting with large targeting vectors
772013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
782013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
792013029509711/07/13Human antibodies to fel d1 and methods of use thereof
802013028075810/24/13Fusion polypeptides capable of activating receptors
812013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
822013026657410/10/13Human antibodies to human angiopoietin-like protein 4
832013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
842013025988110/03/13Fusion polypeptides capable of activating receptors
852013026105610/03/13Vegf antagonist formulations
862013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
872013025491109/26/13Adam6 mice
882013024377509/19/13Multispecific antigen-binding molecules and uses thereof
892013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
902013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
912013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
922013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
932013023053109/05/13Human antibodies to clostridium difficile toxins
942013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
952013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
962013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
972013020949208/15/13Anti-tie2 antibodies and uses thereof
982013021013708/15/13Methods of modifying eukaryotic cells
992013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1002013020949208/15/13Anti-tie2 antibodies and uses thereof
1012013021013708/15/13Methods of modifying eukaryotic cells
1022013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1032013019587808/01/13Anti-asic1 antibodies and uses thereof
1042013019887908/01/13Humanized universal light chain mice
1052013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1062013019587808/01/13Anti-asic1 antibodies and uses thereof
1072013019887908/01/13Humanized universal light chain mice
1082013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1092013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1102013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1112013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1122013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1132013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1142013018581907/18/13Genetically modified major histocompatibility complex animals
1152013018582007/18/13Genetically modified major histocompatibility complex animals
1162013018582107/18/13Common light chain mouse
1172013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1182013018581907/18/13Genetically modified major histocompatibility complex animals
1192013018582007/18/13Genetically modified major histocompatibility complex animals
1202013018582107/18/13Common light chain mouse
1212013017114907/04/13Anti-angptl3 antibodies and uses thereof
1222013017114907/04/13Anti-angptl3 antibodies and uses thereof
1232013016478606/27/13Fucosylation-deficient cells
1242013016478606/27/13Fucosylation-deficient cells
1252013015731306/20/13High affinity antibodies to human il-6 receptor
1262013016015306/20/13Humanized light chain mice
1272013015731306/20/13High affinity antibodies to human il-6 receptor
1282013016015306/20/13Humanized light chain mice
1292013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1302013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1312013013710105/30/13Methods of modifying eukaryotic cells
1322013013710105/30/13Methods of modifying eukaryotic cells
1332013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1342013012983005/23/13Polymer protein microparticles
1352013013037205/23/13Enhanced expression and stability regions
1362013013038805/23/13Methods of modifying eurakyotic cells
1372013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1382013012983005/23/13Polymer protein microparticles
1392013013037205/23/13Enhanced expression and stability regions
1402013013038805/23/13Methods of modifying eurakyotic cells
1412013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1422013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1432013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1442013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1452013011787305/09/13Humanized il-6 and il-6 receptor
1462013011787305/09/13Humanized il-6 and il-6 receptor
1472013010905305/02/13Genetically modified t cell receptor mice
1482013011161605/02/13Genetically modified major histocompatibility complex mice
1492013011161705/02/13Genetically modified major histocompatibility complex mice
1502013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1512013009628704/18/13Restricted immunoglobulin heavy chain mice
1522013008429704/04/13Anti-erbb3 antibodies and uses thereof
1532013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1542013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1552013007867503/28/13High affinity human antibodies to human il-4 receptor
1562013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1572013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1582013003490202/07/13Fusion polypeptides capable of activating receptors
1592013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1602012032210812/20/12Adam6 mice
1612012032349712/20/12Non-hypergeometric overlap probability
1622012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1632012026035710/11/12Low affinity fcgr deficient mice
1642012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1652012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1662012019230007/26/12Common light chain mouse
1672012017868307/12/12Vegf antagonist formulations
1682012016468806/28/12High affinity human antibodies to human nerve growth factor
1692012013501005/31/12High affinity human antibodies to human il-4 receptor
1702012012867905/24/12Human antibodies to the glucagon receptor
1712012011464505/10/12Use of il-1 antagonists to treat pseudogout
1722012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1732012011466505/10/12Human antibodies to human rankl
1742012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1752012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1762012010103504/26/12Vegf antagonist formulations
1772012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1782012009657204/19/12Mice that make vl binding proteins
1792012008792904/12/12Vegf antagonist formulations for intravitreal administration
1802012008300004/05/12Neuropeptide release assay for sodium channels
1812012007679003/29/12Anti-cd48 antibodies and uses thereof
1822012007086103/22/12Human lambda light chain mice
1832012007300403/22/12Hybrid light chain mice
1842012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1852012005207203/01/12High affinity human antibodies to human il-4 receptor
1862012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1872012002140901/26/12Common light chain mouse
1882012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1892012000369701/05/12High affinity antibodies to human il-6 receptor
1902011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1912011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1922011030796612/15/11Mice expressing human voltage-gated sodium channels
1932011030796812/15/11Production of fertile xy animals from xy es cells
1942011029363012/01/11Antibodies to human gdf8
1952011028337611/17/11Methods of modifying eukaryotic cells
1962011026918711/03/11High affinity human antibodies to human il-18 receptor
1972011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
1982011025655610/20/11Humanized fcgr mice
1992011025658710/20/11High affinity human antibodies to human nerve growth factor
2002011025760110/20/11Vegf antagonist formulations for intravitreal administration
2012011025871010/20/11Methods of modifying eukaryotic cells
2022011019545408/11/11Common light chain mouse
2032011018917608/04/11Methods of treating diseases with dll4 antagonists
2042011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2052011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2062011016565007/07/11Fusion polypeptides capable of activating receptors
2072011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2082011015090506/23/11Human antibodies to human delta like ligand 4
2092011015451206/23/11Humanized fc gamma r mice
2102011014593706/16/11Mice that make heavy chain antibodies
2112011010479905/05/11Multifunctional alleles
2122011008168104/07/11Human antibodies to human cd20 and method of using thereof
2132011006590203/17/11High affinity human antibodies to pcsk9
2142011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2152011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2162011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2172011002728602/03/11High affinity human antibodies to human angiopoietin-2
2182011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2192011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2202011000837401/13/11Use of il-1 antagonists to treat gout
2212010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2222010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2232010031662712/16/10Human antibodies to human il-6 receptor
2242010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2252010030443612/02/10Fucosylation-deficient cells
2262010029110711/18/10High affinity human antibodies to human il-4 receptor
2272010029162611/18/10Enhanced expression and stability regions
2282010027993311/04/10Vegf antagonist formulations
2292010023380309/16/10Fusion polypeptides capable of activating receptors
2302010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2312010016676807/01/10High affinity human antibodies to pcsk9
2322010012981705/27/10Identifying germline competent embryonic stem cells
2332010011192105/06/10Use of il-1 antagonists to treat gout
2342010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2352010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2362010004725402/25/10High affinity human antibodies to human il-4 receptor
2372010004233002/18/10Non-hypergeometric overlap probability
2382010003483302/11/10High affinity human antibodies to human il-18 receptor
2392010002147601/28/10High affinity human antibodies to human il-4 receptor
2402009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2412009027188410/29/09Es cell-derived mice from diploid host embryo injection
2422009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2432009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof
2442009016290106/25/09Inducible eukaryotic expression system
2452009015589906/18/09Modified chimeric polypeptides with improved pharmacokinetic properties
2462009015649206/18/09Methods of using il-1 antagonists to treat autoinflammatory disease
2472009014235406/04/09Human antibodies to human delta like ligand 4
2482009013741605/28/09Isolating cells expressing secreted proteins
2492009012344605/14/09Use of il-1 antagonists to treat gout


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo